<DOC>
	<DOCNO>NCT01118962</DOCNO>
	<brief_summary>The purpose obtain data safety seizure frequency associate long-term oral Lacosamide uncontrolled primary generalize tonic-clonic ( PGTC ) seizures subject idiopathic generalize Epilepsy . Additionally , allow subject complete SP0961 ( NCT01118949 ) continue receive Lacosamide .</brief_summary>
	<brief_title>Open-Label Extension Study Assess Safety Seizure Frequency Associated With Lacosamide Primary Generalized Tonic-Clonic Seizures Subjects With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject complete SP0961 ( NCT01118949 ) study Subject expect benefit participation openlabel extension study Lacosamide , opinion investigator Subject meet withdrawal criterion SP0961 ( NCT01118949 ) experience ongoing Serious Adverse Event ( SAE )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Primary Generalized Tonic-Clonic ( PGTC ) Seizures</keyword>
	<keyword>Absence Seizures</keyword>
	<keyword>Myoclonic Seizures</keyword>
	<keyword>Idiopathic Generalized Epilepsy ( IGE )</keyword>
</DOC>